Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

Executive Summary

Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.

Advertisement

Related Content

Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab
10 Things For Pfizer's New CEO To Worry About
Pfizer’s DMD Setback With Domagrozumab Shifts Focus To Gene Therapy Approach
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
CAR-T Drugs Break Ground For Stem Cell Therapies In CNS, Says Brainstorm CEO
After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?
Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel